FOLH1 and prostate cancer: Yoshida et al demonstrated that the extent of bone metastasis and the presence of visceral metastasis on whole-body diffusion weighted imaging (WB-DWI) using METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) score were significantly associated with a shorter cancer specific survival in 72 mCRPC patients.[14] Grubmüller et al demonstrated that PSMA-PET parameters’ change (SUV and PSMA total tumor volume) were significantly associated with PSA response to systemic therapies for mCRPC in 43 patients.[16]